NBIX · Neurocrine Biosciences, Inc.
$156.22
-0.22% last session
End-of-day data · close of 2026-09-11
Market cap
$16B
Enterprise value
$16B
Trailing P/E
22.7
Forward P/E
13.1
Dividend yield
—
Beta
0.38
Avg volume
1M
Employees
2K
Daily Change %
-0.22%
5 Days Change
-0.32%
10 Days Change
0.72%
30 Days Change
-4.20%
60 Days Change
-12.40%
Month to Day Change
-1.03%
Year to Day Change
9.38%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NBIX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-08
Latest call per bank · past 12 months
RBC Capital
Outperform$198
+26.5% vs priceCitigroup
Buy$253
+61.6% vs priceMorgan Stanley
Equal-Weight$182
+16.2% vs priceWells Fargo
Overweight$200
+27.7% vs priceJP Morgan
Overweight$185
+18.2% vs priceUBS
Buy$178
+13.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-08 | RBC Capital | Reiterates | Outperform | $198 |
| 2026-09-03 | Citigroup | Maintains | Buy | $249 → $253 |
| 2026-08-13 | Morgan Stanley | Maintains | Equal-Weight | $196 → $182 |
| 2026-08-03 | Canaccord Genuity | Maintains | Buy | $200 → $210 |
| 2026-08-03 | Truist Securities | Maintains | Buy | $200 → $213 |
| 2026-08-03 | Wedbush | Maintains | Outperform | $185 → $194 |
| 2026-07-31 | Citigroup | Maintains | Buy | $246 → $249 |
| 2026-07-31 | RBC Capital | Maintains | Outperform | $195 → $198 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.2% below the 50-day MA ($164.83).
- Price vs 200-day MA: Trading 5.7% above the 200-day MA ($147.87).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.69) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($123.10) and high ($185.50).
NBIX Price Chart
Loading chart for NBIX…
Fundamentals
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
RDY
Dr. Reddy's Laboratories Ltd
$10B -14.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.